中国药理学与毒理学杂志2012，Vol.26Issue(5)：692-696,5.DOI:10.3867/j.issn.1000-3002.2012.05.018
药物性肝损伤的生物标志物及其评价的研究进展
Progress in biomarkers and evaluation of drug-induced liver injury
摘要
Abstract
Drug-induced liver injury (DILI) is the main serious reaction during drug use and the major component of liver disease. Traditional biomarkers, such as alanine transaminase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, have been irreplaceable in drug-induced liver injury prediction and diagnosis, but in recent years some new biomarkers, such as serum drug-protein adducts, eosinophils, lactate dehydrogenase, gluta-mine dehydrogenase and genomic biomarkers, have been found to be able to make up for the detection sensitivity and specificity of traditional biological markers. This paper summarizes the traditional biomarkers and newly discovered liver injury biomarkers combined with DILI evaluation in order to better forecast and diagnose liver damage while reducing drug harm.关键词
肝损伤/药物毒性/药物评价Key words
liver injuries/drug toxicity/drug evaluation分类
医药卫生引用本文复制引用
高绪聪,柴振海,张宗鹏..药物性肝损伤的生物标志物及其评价的研究进展[J].中国药理学与毒理学杂志,2012,26(5):692-696,5.基金项目
国家科技重大专项基金(2012ZX09505001-001) （2012ZX09505001-001）
